List view / Grid view
6 June 2017 | By Niamh Marriott, Junior Editor
The strategic transaction, which consists of an exchange of Sanofi's animal health business & Boehringer Ingelheim's CHC business, has been closed in market
16 May 2017 | By European Federation of Pharmaceutical Industries and Associations (EFPIA)
The EMA is a world class regulator, whose scientific recommendations are a vital element of the ongoing effort to provide EU citizens with quality medicines
11 May 2017 | By Sarah Wills, Editorial Assistant
An ambitious collaboration between Brainomix, an emerging British business, and Boehringer Ingelheim, one of the world’s largest drug companies, is poised to expedite and improve treatment of stroke, the second biggest killer disease in Europe.
3 May 2017 | By Ivan Blanarik, Senior Vice President and Head of Therapeutic Area Biosimilars at Boehringer Ingelheim
With biosimilars expected to account for 10% of the total biologics market by 2020, we caught up with Boehringer Ingelheim’s Senior VP to find out more…
European Pharmaceutical Review has been keeping the industry informed for 21 years and continues to bring insights into current and emerging technologies, contributions from recognised figures in the life science community and of course, the latest and most up to date news. To celebrate our success, we will be counting down…
12 December 2016 | By Niamh Louise Marriott, Digital Editor
It significantly reduced the risk of (the combined primary endpoint) cardiovascular death, non-fatal heart attack or non-fatal stroke by 14% versus placebo...
21 November 2016 | By Niamh Louise Marriott, Digital Content Producer
BI 695502, a bevacizumab biosimilar candidate to Avastin, is a monoclonal antibody that may slow or stop the growth of certain tumour types by preventing...
12 October 2016 | By Niamh Louise Marriott, Digital Content Producer
The trial investigated overall survival and the reduction in risk of death (14%) was observed for patients treated with afatinib versus gefitinib...
29 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Under the terms of the collaboration, Boehringer Ingelheim receives the right to acquire ViraTherapeutics after conclusion of Phase I clinical development...
13 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Senscis is specifically evaluating nintedanib to understand the disease process and potential benefit of the compound to treat SSc-ILD...
13 July 2016 | By Victoria White, Digital Content Producer
Lilly and Boehringer Ingelheim are to collaborate on a Phase Ib study of abemaciclib and BI 836845 in patients with HR+, HER2- metastatic breast cancer...
30 June 2016 | By Victoria White, Digital Content Producer
INMARK is a study investigating the effect of Ofev (nintedanib) on changes in specific blood biomarkers in patients with idiopathic pulmonary fibrosis...
27 June 2016 | By Victoria White, Digital Content Producer
Sanofi and Boehringer Ingelheim have signed contracts to secure the exchange of Sanofi's Merial and Boehringer Ingelheim's consumer healthcare business...
14 June 2016 | By Victoria White, Digital Content Producer
Jardiance reduced the risk for new-onset or worsening kidney disease by 39% versus placebo in adults with type 2 diabetes with established CV disease...
13 June 2016 | By Victoria White, Digital Content Producer
New data for Jardiance (empagliflozin) show that reduced risk for cardiovascular (CV) death was consistent across age groups in adults with type 2 diabetes...
